Related Experiment Video
Updated: Jun 4, 2026
A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
Antitumor Immunity Mediated by Nanoreactors Based on Bacterial Membrane Vesicles
Ruixin Zhang1, Yue Sun2, Fang Ding1
1National Engineering Laboratory for Resource Development of Endangered Chinese Crude Drugs in Northwest China; Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry, the Ministry of Education; College of Life Sciences, Shaanxi Normal University, Xi'an 710119, China.
Abstract:
Traditional cancer vaccines are designed to elicit tumor-specific immune responses against preexisting or recurrent tumors and have been widely explored in oncology. However, their clinical translation has been hampered by persistent limitations such as suboptimal immunogenicity, complex manufacturing processes, and safety concerns, underscoring the need for multifunctional cancer vaccines that simultaneously achieve high potency and favorable tolerability. Here, we present a tumor vaccine platform based on engineered bacterial membrane vesicles (E-MVs) displaying the well-defined tumor-associated antigen MUC1 VNTR. This platform integrates antigen delivery with the intrinsic adjuvant properties of E-MV biological macromolecule, thereby enabling both therapeutic antitumor immunity and durable prophylactic protection. E-MVs derived from engineered Escherichia coli Rosetta (DE3) exhibit a spherical morphology with a size distribution of 100-200 nm. Following subcutaneous administration, E-MVs rapidly accumulate in draining lymph nodes and are efficiently internalized by dendritic cells, promoting antigen processing and cross-presentation to T cells. Functionally, E-MVs induce significant infiltration of CD8+ T cell into the tumor microenvironment and enhance IFN-γ production, resulting in potent tumor immune responses. This leads to suppressed tumor growth, prolonged survival, and effective prevention upon tumor challenge in both "cold tumor" (breast cancer) and "hot tumor" (melanoma) mouse models. Collectively, these results demonstrate that the E-MV-based vaccine is a versatile therapeutic and prophylactic platform, offering a simple, efficient, and clinically translatable strategy to induce durable antitumor immunity.
Insights
This study introduces engineered bacterial membrane vesicles (E-MVs) as a novel cancer vaccine platform. E-MVs effectively deliver tumor antigens and stimulate potent immune responses, offering both therapeutic and prophylactic benefits against various cancers.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Traditional cancer vaccines face challenges including low immunogenicity, complex manufacturing, and safety issues, limiting their clinical use.
- There is a critical need for advanced cancer vaccines that offer high efficacy and good tolerability.
- Multifunctional vaccine platforms are required to overcome the limitations of current cancer immunotherapies.
Purpose of the Study:
- To develop and evaluate a novel tumor vaccine platform utilizing engineered bacterial membrane vesicles (E-MVs).
- To assess the potential of E-MVs displaying MUC1 VNTR antigen for both therapeutic and prophylactic antitumor immunity.
- To investigate the immunogenicity and efficacy of E-MV-based vaccines in preclinical cancer models.
Main Methods:
- Engineered bacterial membrane vesicles (E-MVs) were produced from *Escherichia coli* Rosetta (DE3) and loaded with the MUC1 VNTR tumor antigen.
- E-MVs were characterized for morphology and size distribution (100-200 nm).
- Subcutaneous administration in mouse models assessed E-MV biodistribution, immune cell uptake, T cell activation, and antitumor effects in cold and hot tumors.
Main Results:
- E-MVs efficiently accumulated in draining lymph nodes and were internalized by dendritic cells, promoting T cell cross-presentation.
- E-MV vaccination induced significant CD8+ T cell infiltration and IFN-γ production, leading to potent antitumor immune responses.
- The E-MV vaccine suppressed tumor growth, prolonged survival, and provided protection against tumor challenge in breast and melanoma models.
Conclusions:
- Engineered bacterial membrane vesicles (E-MVs) represent a versatile and potent platform for cancer vaccines.
- This E-MV platform integrates antigen delivery with intrinsic adjuvant properties, enabling both therapeutic and prophylactic antitumor immunity.
- The E-MV vaccine strategy is simple, efficient, and shows promise for clinical translation in inducing durable antitumor immunity.
More Related Videos
07:33Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
Published on: September 28, 2022
11:07Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
Published on: April 29, 2015
Related Concept Videos
01:27Tumor Immunotherapy
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...